Canine autoimmune hemolytic anaemia : management challenges by Skelly, Barbara & Swann, James
AUTH
OR
PROO
F 
COPY
 
Not fo
r 
public
ation
© 2016 Swann and Skelly. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. 
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
© 2016 Swann and Skelly. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Veterinary Medicine: Research and Reports 2016:7 101–112
Veterinary Medicine: Research and Reports Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
101
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/VMRR.S81869
Canine autoimmune hemolytic anemia: 
management challenges
James W Swann1 
Barbara J Skelly2
1Queen Mother Hospital for Animals, 
The Royal Veterinary College, 
Hatfield, Hertfordshire, 2Department 
of Veterinary Medicine, University of 
Cambridge, Cambridge, UK
Abstract: Immune-mediated hemolytic anemia is one of the most common manifestations of 
canine immune-mediated disease, yet treatment regimens remain nonstandardized and, in some 
cases, controversial. The main reason for this, as for most diseases in veterinary medicine, is the 
lack of large-scale placebo-controlled trials so that the efficacy of one treatment over another 
can be established. Most of the evidence used for treatment comes from retrospective studies 
and from personal preference and experience, and because of this, treatment regimens tend to 
vary among institutions and individual clinicians. Management of immune-mediated hemolytic 
anemia includes immunosuppression, thromboprophylaxis, and supportive care measures to 
help prevent and treat concurrent conditions.
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Introduction
Immune-mediated hemolytic anemia (IMHA) is considered to be the most common 
autoimmune disease in dogs1 and is encountered in first opinion and specialist practices 
in North America and Europe. Clinical features of the disease are the result of a spon-
taneous autoimmune response directed against normal glycoprotein molecules on the 
surface of the erythrocyte.2 Production of autoreactive antibodies during this response 
results in destruction of erythrocytes, either by complement-mediated lysis (so-called 
intravascular hemolysis) or due to phagocytosis by cells of the monocyte–phagocyte 
system in the liver and spleen (extravascular hemolysis). These processes result in 
anemia and, in some cases, prehepatic icterus due to accumulation of unconjugated 
bilirubin.
Following diagnosis, many dogs with IMHA receive blood products that are 
intended to achieve cardiovascular stability by improving the delivery of oxygen to 
peripheral tissues. A number of clinical parameters, grouped together as the Anemic 
Dog Clinical Assessment Score, have been evaluated as guides for administration of 
transfusions3; however, there is currently no consensus regarding the optimal trigger 
for this procedure in dogs. The availability of blood products varies according to geo-
graphical location and type of veterinary practice, with some institutions maintaining 
colonies of donor animals and others relying on client-owned dogs or on charitable 
blood donation services for their supply.4
Glucocorticoid products are commonly used for treatment of IMHA in dogs; in a 
recent systematic review of studies produced at tertiary referral institutions, we found 
that these drugs had been administered to all of the dogs included in the review.5 
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Table 1 Summary of two different prognostic scores developed 
for use in dogs with immune-mediated hemolytic anemia
Score Parameter Definition Score
CHAOS  
(Whelan et al)16
Age ≥7 years 2
Rectal temperature ≥38.9°C 1
Persistent agglutination after 
dilution in saline
Positive 1
Serum albumin concentration <30 g/L 1
Serum bilirubin concentration ≥85.5 µmol/L 2
Total possible score 7
Ishihara et al17 Sex Male 1
Season Warm 1
Packed cell volume <20% 1
Platelet count <200×103/µL 1
Serum total protein 
concentration
<6 g/dL 1
Total possible score 5
Abbreviation: CHAOS, canine haemolytic anaemia objective score.
Several other immunosuppressive drugs also have been used 
to treat the disease, including azathioprine,6,7 leflunomide,8 
ciclosporin,9,10 and mycophenolate mofetil.11,12 There is 
currently no consensus among veterinarians regarding the 
optimal immunosuppressive regimen that should be used 
after a dog has been diagnosed with IMHA, and there has 
been considerable variation in the choice, dosage, duration, 
and rate of reduction of drugs used in studies published in 
the past 20 years.5
IMHA is considered to have a poor prognosis in dogs, 
with mortality rates of 50%–70% reported in older studies,6,13 
and rates of ~30%–40% in more recent studies,14 presum-
ably reflecting improvements in awareness of disease, speed 
of diagnosis, and availability of supportive care and blood 
products. A number of previous studies have investigated the 
associations between survival and the biochemical, hema-
tologic, or clinical parameters that can be measured at pre-
sentation to determine whether these might have prognostic 
value. Review of the studies that assessed prognostic factors 
using a multivariable statistical model revealed that serum 
bilirubin and urea concentrations had each been significantly 
associated with survival in more than one previous study,15 
suggesting that these variables might be helpful in guiding 
clinical decisions in future.
Predicting disease outcome using 
scoring systems
Because clinical presentation and response to treatment are 
variable in dogs with IMHA, a number of scoring systems 
have been developed to estimate the severity of disease and 
prognosis for dogs when they are diagnosed. These scores 
have been generated by investigating associations between 
individual clinicopathological variables and outcome, mea-
sured as survival time after diagnosis or percentage mortality 
at a defined time point. Summaries of two different prognostic 
scores are presented in Table 1. In a recent study, Goggs 
et al14 found that a combination of the American Society 
of Anesthesiologists’ clinical grade and serum concentra-
tions of bilirubin and urea or creatinine predicted mortality 
with greater accuracy than either of the scores described by 
Whelan et al16 or Ishihara et al17 in a sample of 276 dogs in 
the British Isles, but the authors unfortunately did not present 
their own model in the same form of a user-friendly score. An 
additional study revealed that the score developed in Japan 
did not predict survival in dogs with IMHA in Australia,18 
highlighting the importance of using prognostic tools in a 
population for which they have been validated.
Development of “intravascular hemolysis”, a term used 
inconsistently to describe some combination of hemoglobin-
uria, hemolysed plasma, and presence of persistent agglutina-
tion of red blood cells, has traditionally been considered an 
indicator of a poor prognosis in dogs with IMHA. However, 
this perception is not supported by the majority of clinical 
studies of factors associated with survival: only two studies 
indicated using univariate analyses that autoagglutination 
was associated with decreased survival. One of these studies 
subsequently showed no difference between cases that had 
or did not have undefined “intravascular hemolysis”,19 while 
the other demonstrated that agglutination was associated 
with survival to discharge but not to 1 year after diagnosis.20 
In contrast, serum total bilirubin concentration, which is an 
indicator of the severity of either intravascular or extravascu-
lar hemolysis, has been associated consistently with survival 
in several previous studies that utilized either univariate or 
multivariate analyses, albeit with considerable variation in 
the apparent size of the effect.10,13–15,19,21–24 Consequently, we 
believe that this variable is likely to be the most useful for 
the clinician in guiding therapy and estimating prognosis, 
particularly because it is easily measured in the majority of 
primary care and specialist practices.
Complications of conventional 
treatment
The use of glucocorticoids and  
their side effects
Corticosteroids, mainly the glucocorticoid – prednisolone, 
have been the mainstay of treatment for many years. No 
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protocols are described that do not include corticosteroids, 
probably because many would consider it unethical to conduct 
a treatment trial that withholds this class of drugs.25 When 
other drugs are assessed for their usefulness in IMHA, they 
are given in conjunction with corticosteroids and compared 
to steroids alone. There have been no known multiple-patient 
published trials that have shown that any other immunosup-
pressive drug can be used alone in the management of IMHA, 
although anecdotal reports have suggested that this may be 
possible and ciclosporin has been used for this purpose by 
these authors in circumstances when owners have refused 
to use steroid therapy due to the side effects encountered.
Inflammatory responses are regulated by creating a bal-
ance between signals that stimulate and those that suppress. 
Endogenous glucocorticoids have a physiological role in 
suppression/modulation of inflammatory responses. Chronic 
autoimmune and inflammatory diseases develop when the 
stimuli to perpetuate the immune response outweigh the abil-
ity of endogenous glucocorticoids to suppress the response. 
This results in the hyperactivation of the immune system 
characteristic of these diseases. Treatment with synthetic 
glucocorticoids is used to control immune-mediated disease, 
taking advantage of the fact that endogenous glucocorticoids 
regulate immune responses.
Although steroids are undeniably effective at treating 
IMHA, they do so with a number of potentially severe side 
effects that have an impact on an owner’s willingness to con-
tinue with treatment. Steroids cause polydipsia and polyuria 
through their interference with antidiuretic hormone function, 
polyphagia, panting, restlessness, muscle weakness and wast-
ing, thromboembolic disease, and proteinuria. These signs 
of iatrogenic hyperadrenocorticism can be mild to severe 
and sometimes life threatening. In people, steroid use is 
much more restricted by side effects, and hypertension and 
osteoporosis are commonly seen. For this reason, it is rare 
that immune-mediated diseases in humans are managed with 
steroids alone, and other drugs, splenectomy, and monoclonal 
antibody treatments are used both for their efficacy and for 
their steroid-sparing effects.26
Steroids have the ability to worsen the clinical signs in 
an animal that already has signs of disease in another body 
system. An example of this would be the ability of steroid 
therapy to induce or worsen congestive heart failure in a 
dog with preexisting heart disease (eg, mitral valve endo-
cardiosis or occult cardiomyopathy). In human medicine, the 
long-accepted recommendations are to avoid glucocorticoid 
administration in patients with heart failure due to the sodium 
and water retention they induce. More recently, it has been 
suggested that glucocorticoids may actually act synergisti-
cally with diuretics in some patients to improve diuresis and 
therefore clinical well-being. This area has not been explored 
in dogs and, as such, specific recommendations are difficult 
to justify.27
The drugs and their dosing regimens commonly used for 
the management of IMHA along with other management 
options are summarized in Table 2.
Opportunistic infections
Veterinarians managing dogs with IMHA may be concerned 
about the possibility of opportunistic infections when 
administering immunosuppressive drugs at high doses or in 
combinations, and a number of different infectious complica-
tions have been reported with the use of ciclosporin, alone or 
in combination with glucocorticoids. These include fungal 
infections,30 bacterial urinary tract infections,34 disseminated 
nocardiosis,35–37 and papillomavirus-induced lesions,38 but 
there is little evidence available in dogs to indicate how often 
these complications arise.
In people, opportunistic infections do occur in patients 
receiving immunosuppressive therapy for a number of differ-
ent autoimmune diseases and following transplantation.39,40 
These appear to affect the respiratory tract most commonly, 
resulting in pneumonia with or without the involvement of 
the opportunistic organism Pneumocystis jirovecii. The latter 
organism could present a theoretical risk to dogs receiving 
immunosuppressive therapy but has been reported only 
in dogs with immunoglobulin deficiency, with or without 
B-cell hypoplasia.41–43 Immunocompromised people are 
also predisposed to development of active infections with 
Toxoplasma gondii, and a number of case reports indicate 
that similar complications could occur in dogs treated with 
immunosuppressive drugs due to reactivation of latent 
T.  gondii and Neospora caninum infections.44–46
Management of complex cases
Failure to control the disease/relapses
This section is illustrated by two case examples presented 
below.
Case example 1
Signalment
Six-year-old male whippet; weight: 16 kg.
History
This dog had a history of immune-mediated thrombocyto-
penia that had been previously treated with prednisolone 
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Table 2 Management options for IMHA
Drug or 
management 
method
Dose Mechanism of action Adverse effects Cost and practicalities 
of use
Steroids
Glucocorticoid Prednisolone: 2 mg/kg/d 
reducing to 1 mg/kg/d after 
2–4 weeks;dexamethasone:  
0.2–0.3 mg/kg/d until oral 
medication can be started
Alters gene 
transcription;downregulates  
Fc receptor expression,  
decreases antigen processing,  
and suppresses T-cell function
PU/PD, polyphagia, panting,  
muscle wasting, weight gain, 
opportunistic infections,  
GI ulceration, diabetes mellitus, 
osteoporosis, thromboembolic  
disease
Inexpensive; 1 mg, 
5 mg, and 25 mg tablets 
available; injectable 
dexamethasone 
convenient if vomiting 
present
Anabolic steroid Nandrolone: 1–5 mg/kg 
intramuscularly/ 
subcutaneously, maximum  
dose 40–50 mg per dog; 
repeated every 21 days
Thought to stimulate  
erythropoiesis in nonregenerative 
anemia; mechanism unproven
Sodium, calcium, potassium, 
chloride, phosphate retention; water 
retention; hepatotoxicity, behavioral 
changes, reproductive abnormalities 
(oligospermia, estrus suppression)
Parenteral form only; 
easy to administer; lack of 
information about efficacy 
means anabolic steroids 
are rarely recommended
Steroid-sparing drugs
Azathioprine 2 mg/kg/d po for no more  
than 14 days; then decrease  
to 1 mg/kg po every day or 
2 mg/kg EOD depending on  
ease of dosing; or, 50 mg/m2 
every other day
Thiopurine analog Hepatotoxicity,28 bone marrow 
suppression, pancreatitis; most side 
effects follow use of 2 mg/kg daily 
dosing for >2 weeks though side 
effects can occur in dogs that have 
pre-existing disease in these organs  
or disease susceptibility
Inexpensive (25 mg 
and 50 mg tablets); 
other doses have to be 
reformulated; do not split 
tablets; not licensed for 
use in dogs in the UK
Ciclosporin 2.5–5 mg/kg, po, q12h Calcineurin inhibitor GI signs (vomiting, diarrhea,  
anorexia), gingival hyperplasia,29 
opportunistic infections;30  
ciclosporin is not cytotoxic and is  
not myelosuppressive as it is  
specific for lymphocytes
Expensive; capsules 
available in 10 mg, 25 mg, 
50 mg, and 100 mg 
formulations; liquid 
formulation available; not 
licensed for use for this 
condition but licensed for 
use in dogs in the UK
Mycophenolate 
mofetil
10 mg/kg, po, q12h Purine synthesis inhibitor GI upset, lethargy, hepatotoxicity, 
bone marrow suppression
250 mg and 500 mg 
capsules; available as 
Cellcept and also in 
generic form; not licensed 
for use in dogs in the UK
Leflunomide 1–4 mg/kg, po, q24h Pyrimidine synthesis inhibitor GI upset, bone marrow  
suppression, hepatotoxicity
10 and 20mg tablets
Not licensed for use in 
dogs in the UK
Lithium carbonate 10–11 mg/kg orally, bid Stimulates erythropoiesis Diarrhea, hypersalivation,  
seizures, increased liver  
enzymes, PU/PD
Little information about 
use in dogs; serum levels 
should be measured;31,32 
not licensed for use in 
dogs in the UK
Rescue therapies
hIVIg 0.5–1.0 g/kg, iv, over 
6–12 hours
Fc receptor blockade Thromboembolic disease,  
volume overload, anaphylaxis
Expensive; do not repeat 
infusion; not licensed for 
use in dogs in the UK
Plasmapheresis N/A Microporous membrane 
separation of plasma from other 
blood components before 
immunoglobulins are filtered from 
plasma to limit immune response
Hypocalcemia due to anticoagulants 
in circuit
Requires specialist 
equipment/expertise; 
limited experience in 
dogs33
Splenectomy N/A Underlying etiology of IMHA 
involves antibody-mediated red  
cell destruction by the spleen; 
removal of spleen removes site  
of destruction
Increased susceptibility to infectious 
agents, risks associated with  
anesthesia and surgery in a dog  
with IMHA (thromboembolic  
disease etc)
One-off surgical and 
aftercare costs; patient 
needs to be stabilized 
for anesthesia – usually 
requires transfusion
Abbreviations: bid, twice daily; GI, gastrointestinal; hIVIg, human intravenous immunoglobulin; IMHA, immune-mediated hemolytic anemia; N/A, not applicable; po, per os; 
q12h, every 12 hours; q24h, every 24 hours; EOD, every other day; PU/PD, polyuria/polydipsia; iv, intravenous.
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Management of canine autoimmune hemolytic anemia
and  azathioprine. The treatment had been tapered off and 
had stopped completely 9 months prior to the dog becoming 
unwell again.
The dog had a 3-week history of lethargy and inappetence. 
He was identified as having a regenerative anemia at his pri-
mary practice (packed cell volume [PCV]: 25%) and was put 
on treatment using prednisolone at a dose rate of 1 mg/kg/d 
initially, which was increased to 2 mg/kg/d 12 days before 
referral because the initial response to treatment was poor. 
Although the response to the dose increase was positive at 
first (PCV increased to 42%), the dog again deteriorated, the 
PCV dropped, and he was referred to the Queen’s Veterinary 
School Hospital.
This was a client-owned animal. Owner consent was 
obtained plus consent for the use of drugs not licensed in 
this species. This was in no way an experimental procedure 
but was an attempt to rescue a clinical case from dramatic 
deterioration using licensed and non-licensed drugs that are 
reported to be useful in these cases.
Clinical examination
The dog was lethargic but reasonably bright. He had normal 
temperature and respiratory rate, and a heart rate of 80 bpm. 
His mucous membranes were pale and icteric. His tempera-
ture was 38.9°C.
Investigation
Blood work showed moderate anemia (PCV: 25%), with 
evidence of regeneration and spherocytosis. There was 
mild thrombocytopenia (platelet count: 109×109/L; range: 
175–500×109/L). Total protein was 74 g/L (60–80 g/L). 
Bilirubin was mildly increased (56 mmol/L; range: 
0–12 mmol/L). Coombs test was negative. In-saline agglu-
tination test was positive.
Survey radiographs of thorax and abdomen revealed 
no abnormalities, and abdominal ultrasonography was 
unremarkable.
Diagnosis
The history, clinical examination, and laboratory findings 
were compatible with a diagnosis of immune-mediated 
hemolytic anemia (IMHA).
Management
The dog continued to be on prednisolone (2 mg/kg/d) and 
azathioprine was added (2 mg/kg/d). Over the next 24 hours, 
the dog’s condition deteriorated significantly and he became 
pyrexic, lethargic, pale, and tachypneic. His PCV was found 
to have dropped to 11%. He was given one unit of packed 
red cells, and his posttransfusion PCV was 25%. He also 
received 10 g of human intravenous immunoglobulin (hIVIg) 
as a constant rate infusion over 4 hours.
The dog was sent home with PCV stable at 20% 
and receiving prednisolone (2 mg/kg/d), azathioprine 
(2 mg/kg/d), ciclosporin (3 mg/kg, bid), and clopidogrel 
(56.25 mg/d).
The dog returned to the hospital for reassessment after 
3 days, by which time his PCV was 25% with a strongly 
regenerative response. Ciclosporin caused persistent diar-
rhea in this dog and was tapered and discontinued over 
2 weeks. After 2 weeks, the prednisolone dose was decreased 
to 1 mg/kg/d. A recheck after 1 month showed that the PCV 
had increased to 44%, and the dog was doing well.
Medication was maintained at immunosuppressive levels 
for 3 months, then a tapering regimen began.
Discussion
This case shows that in dogs with a predisposition for immune-
mediated disease, different diseases can present either at the 
same time or, as in this case, serially in a dog’s lifetime. When 
therapy with prednisolone was started to treat IMHA, it began 
at the fairly modest dose of 1 mg/kg/d. Although this was 
increased after 7 days, response was transient. The dog then 
deteriorated rapidly, having been relatively stable for a period 
of about 3 weeks. Treatment intensity was increased using 
azathioprine, but this drug is thought not to have rapid onset 
of action and probably did little to prevent the hemolytic crisis 
that the dog entered. hIVIg was chosen at this point because 
of its perceived rapid onset of action. This patient responded 
well both clinically and hematologically and was discharged 
from the hospital in a stable condition.
Case example 2
Signalment
Eight-year-old male, entire, Irish setter dog; weight 42 kg.
History
This Irish setter had a history of reduced exercise tolerance, 
disorientation and collapse on exercise, and tachypnea. He was 
hypothyroid and had been receiving thyroid supplementation.
This was a client-owned animal. Owner consent was 
obtained.
Clinical examination
The dog was bright and appeared normal in attitude. He had 
a normal temperature; respiratory rate was 56 bpm and heart 
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rate was 150 bpm. His mucous membranes were pale, with 
a normal capillary refill time. His abdomen appeared to be 
pendulous, with suspected cranial abdominal organomegaly.
Investigation
Blood work showed marked anemia (PCV: 14%), with no 
evidence of regeneration. There was marked leukocytosis 
along with neutrophilia (31.56×109/L; range: 3–11.5×109/
L). There was marked thrombocytosis (platelet count: 
2,275×109/L; range: 175–500×109/L). Total protein was 
70 g/L (range: 60–80 g/L). No spherocytosis or in-saline 
agglutination was seen. Bilirubin was normal (3.1 mmol/L; 
range: 0–12 mmol/L). Coombs test was negative.
Survey radiographs of thorax and abdomen revealed 
no abnormalities, and abdominal ultrasonography was 
unremarkable.
Bone marrow aspiration and core biopsy were suggestive 
of pure red cell aplasia (PRCA) as there were few to no red 
cell precursors identified. The majority of cells were myeloid, 
with evidence of maturation to the segmented neutrophil stage.
Diagnosis
The history, clinical examination, and laboratory findings 
were compatible with a diagnosis of PRCA of presumed 
immune-mediated etiology in the absence of any other 
pathological changes.
Management
The dog was treated with prednisolone (2 mg/kg/d) and 
ciclosporin (2.5 mg/kg, bid). He remained nonregenerative 
and was transfusion dependent for the following 3 weeks. 
At this point, lithium carbonate (10 mg/kg, bid) was added 
to his dosage regimen. Three weeks later, when again the 
dog required transfusion, ciclosporin was withdrawn and 
mycophenolate mofetil was added (10 mg/kg, bid)
Outcome
No improvement was seen in the red cell parameters, and 
no indication of regeneration was seen. In addition, the dog 
developed a skin lesion on the bridge of his nose, which 
cytologically was found to contain fungal hyphae. Lithium 
carbonate dose was decreased to 10 mg/kg/d following some 
adverse effects. The dog continued to do badly, however, 
made no response to mycophenolate, and was euthanized due 
to both absence of response to treatment and the development 
of hemorrhagic gastroenteric signs.
Discussion
This dog illustrates some of the frustrations encountered 
with bone marrow-centered disease. There were few indi-
cations of the etiology of the anemia in this Irish setter 
and the disease was presumed to be immune mediated in 
the absence of any other drug-related, toxic, neoplastic, or 
inflammatory disease. The dog was supported with trans-
fusions and was immunosuppressed. When there was no 
response, other additional therapies were used, including 
lithium carbonate and then mycophenolate mofetil. Lithium 
has a small body of literature to support its use and was 
not helpful in this case (Table 1). Mycophenolate has been 
reported in small numbers of canine IMHA cases and was 
reported to provoke few side effects in canine patients when 
used in conjunction with steroids. It may prove useful as 
an alternative agent in the management of this disease.11 
Unfortunately, it also was not helpful in this case, and the 
dog was euthanized.
Survival curves constructed from data obtained from dogs 
with IMHA show curves with similar slopes reflecting the fact 
that most deaths occur in the first 2 weeks after diagnosis.13,24,47 
Problems arise when immunosuppressive regimens are insti-
tuted and there is either no control of the hemolytic process 
or no regenerative state is achieved. In these circumstances, 
clinicians often look to increase the breadth of the immunosup-
pression by adding other agents. Most dogs achieve initial con-
trol using prednisolone ± another agent, usually azathioprine 
or ciclosporin. When there is a less-than-optimal response to 
treatment, other agents are added, including azathioprine and 
ciclosporin, to increase to two immunosuppressive agents or 
three depending on whether the dog was on mono or dual 
therapy to begin with. If this does not alter the disease process, 
there are a number of options for clinicians, none of which is 
the accepted and evidence-proven route.
Several studies have looked at the role of human intrave-
nous immunoglobulin (hIVIg) for this purpose. As far back 
as 1997, Kellerman and Bruyette suggested that hIVIg would 
be a good option for dogs that did not respond to predniso-
lone therapy within 7 days.48 This was reiterated by a later 
study,49 but better long-term survival was not proven.50,51 In 
one published prospective study, again hIVIg did not alter 
response to treatment or survival,23 although the survival data 
compared favorably to those in other studies (24/28 survived 
to 2 weeks, 86%). The question that has not been answered by 
these studies is whether hIVIg is able to alter prognosis and 
survival in a dog that would not otherwise have responded 
to standard medication, ie, one that would be expected to 
have a poor prognosis based on our current understanding 
of prognostic markers. For this to be answered, clinicians 
would have to have at their disposal a robust prognostic scor-
ing system that could reliably pick out dogs that may benefit 
from more intensive drug regimens.
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In the literature on human medicine, a strong case is made 
for the role of splenectomy in IMHA patients, with survival 
rates encouragingly high.52 The idea that splenectomy may be 
helpful is decades old in veterinary medicine too, with reports 
dating back to 1985 reporting 100% survival in three dogs 
with IMHA.53 More recently, a retrospective study evaluated 
ten dogs that were splenectomized as part of their treatment 
for IMHA.54 This study showed 90% survival at 30 days, 
with packed cell volumes (PCVs) rising significantly 3 days 
after the procedure and reduced requirement for transfusion. 
These studies appear to suggest that IMHA could be managed 
successfully by splenectomy and that this technique warrants 
further investigation through a larger-scale prospective study.
Disease relapse also poses problems for IMHA cases. 
Recommended treatment times vary anecdotally between 
3 months and 6 months and are rarely standardized, though 
some authors55 have found it helpful to use standard protocols 
within their institution, with the result that retrospective stud-
ies become more meaningful and data collection is easier. 
The treatment regimen described at Utrecht, the Netherlands, 
follows a 69-day gradually tapering course. Relapses prompt 
a return to the beginning of the regimen. Too rapid tapering 
has been associated with increased incidence of relapse, but 
strong evidence for this is lacking in the literature.
Nonregenerative immune-mediated 
anemia
Classically, IMHA is diagnosed when an animal has a 
regenerative anemia associated with autoagglutination, 
Coombs test positivity, and spherocytosis in the absence of 
any recognizable underlying disease pathology. The regen-
erative response does not happen immediately, however, 
and 3–5 days are required before an adequate reticulocyte 
response is recognized after acute hemolysis. If there is no 
appropriate reticulocyte response after 5 days, then it is 
still possible that immune-mediated disease is the cause, 
and animals may have either pure red cell aplasia (PRCA) 
or nonregenerative IMHA.56 PRCA is diagnosed when 
erythroid aplasia results from presumed immune-mediated 
destruction of precursor cells within the bone marrow.56–58 
Nonregenerative IMHA appears to be a related disorder in 
that immune-mediated red cell destruction takes place within 
the marrow, and maturation arrest of the erythroid lineage at 
different stages of maturation can be recognized. In addition, 
some forms of nonregenerative IMHA are associated with 
bone marrow erythroid hyperplasia59 and other pathological 
changes such as dysmyelopoiesis, myelonecrosis, myelofibro-
sis, and hemophagocytic syndrome. Dogs that have similar 
hematological changes peripherally can therefore have very 
different bone marrow profiles varying from PRCA to ery-
throid hyperplasia.
Although the names PRCA and nonregenerative IMHA 
have been given to these conditions based on the cytologi-
cal evaluation of the bone marrow, from a purely clinical 
perspective, it would appear that PRCA is just one end of 
a continuum of immune-mediated disease, which begins as 
destruction of early precursors and ends with destruction of 
mature circulating cells. These diseases all have the same 
feature of immune-mediated cell lysis and should all respond 
to immunosuppression, albeit to different degrees. Giving a 
specific disease name, such as PRCA, suggests it is a separate 
disease entity and somehow is unrelated to peripheral IMHA. 
We would argue that these diseases are closely related and are 
only separated by the stage of maturation of the cell type that 
is the specific target for autoantibody production. As such, 
management regimens are similar in all cases.
The prognosis for dogs with PRCA is reported to be 
fair within the available literature, with survival rates of 
72%–79%.56,59 However, numbers are low and the authors’ 
 perception is that these diseases are more difficult to man-
age. In one study,59 dogs with nonregenerative IMHA and 
erythroid hyperplasia were shown to have statistically sig-
nificant lower 60-day survival rate (56%) when compared 
with dogs showing maturation arrest or PRCA. Again, low 
numbers make this information open to interpretation. Many 
clinicians would choose a more aggressive multidrug form 
of therapy from the outset for these cases or would ramp up 
therapy after treatment with steroid alone fails to resolve the 
disease within a reasonable timeframe (10–14 days). The evi-
dence for such choices is lacking, however, and because 
much of the literature is ≥8 years old, it does not include 
information about newer drug choices such as mycophenolate 
or even ciclosporin.
Thromboembolic disease
Formation of thrombi is one of the major complications 
suffered by dogs with IMHA,47,60 and the pathophysiology 
of this process has been reviewed elsewhere.61 Pulmonary 
thromboembolism (PTE) is reported most commonly, but 
vessels in other locations, including the brain, spleen, portal 
vasculature, and kidneys, may be affected.22,24,62 One of the 
major challenges involved in managing PTE in dogs with 
IMHA is the difficulty in diagnosing this complication ante 
mortem. Formation of a thrombus does not result in reliable 
changes in the radiographic appearance of the lungs,63 nor 
does it consistently cause hypoxemia in all cases.64 A recent 
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study indicated that computed tomography with pulmonary 
angiography, which is considered the gold standard imag-
ing modality for diagnosis of PTE in people, might produce 
greater diagnostic accuracy,65 but this form of imaging is 
expensive and not readily available in clinical practice. As a 
result, PTE is often suspected if there are consistent clinical 
and laboratory findings, such as acutely increased respiratory 
rate and effort, hypoxemia, and increased alveolar-to-arterial 
oxygen gradient,66 but it may be difficult to establish whether 
these changes could have a different etiology, such as second-
ary bacterial pneumonia, acute respiratory distress syndrome, 
or increased respiratory drive due to cerebral hypoxia.
There has been frequent speculation that development of 
thromboembolic disease is predictive of poor outcome in dogs 
with IMHA,22,62 but definitive proof of this hypothesis is lack-
ing, partly due to the difficulty in confirming the existence of 
the problem in live animals. Paradoxically, greater maximal 
amplitude values obtained by thromboelastography in dogs 
with IMHA were associated with improved survival,67,68 prob-
ably because development of consumptive coagulopathy is 
associated with poor prognosis.
Due to its importance as a possible cause of additional 
morbidity and mortality, there has been extensive discussion 
of the use of anticoagulant therapy, either for symptomatic 
animals or as prophylaxis for those recently diagnosed with 
the disease.61 These discussions are somewhat hampered by 
an incomplete understanding of the processes that result in 
a systemic hypercoagulable state and increased risk of clini-
cally detectable thromboembolic disease, as well as by the 
lack of concrete evidence to support an association between 
development of thromboembolic disease and increased risk 
of death.
Among the drugs evaluated in clinical practice, some 
inhibit platelet activation (aspirin and clopidogrel) and some 
limit the activity of coagulation factors (unfractionated and 
low-molecular-weight heparin). As with immunosuppressive 
treatment, there is no consensus among veterinarians as to the 
preferred form of anticoagulant therapy,5 and it is likely that 
requirements will differ widely between individual patients 
according to the severity of their disease.
A large retrospective study investigated the outcome asso-
ciated with several different anticoagulant regimens that were 
administered to dogs with IMHA shortly after diagnosis and 
alongside a standardized immunosuppressive protocol that 
included prednisone and azathioprine.60 This study demon-
strated that administration of aspirin at an “ultra-low” dose of 
0.5 mg/kg twice daily resulted in improved survival, compared 
to dogs that received no anticoagulant drug, heparin alone, 
or a combination of aspirin and heparin. A smaller prospec-
tive and randomized study evaluated the use of clopidogrel 
alone, ultra-low-dose aspirin alone, or a combination of the 
two drugs, but this did not reveal any significant difference in 
survival between the three regimens.69 While apparently not 
supporting the use of clopidogrel in dogs with IMHA, this 
study is likely to have been underpowered, recruiting just six 
cases per group. There is suspicion that a proportion of dogs 
with IMHA will also have platelets that are relatively resistant 
to the action of aspirin, as has been reported in people. In this 
situation, it may be of benefit to consider the use of an alter-
native antiplatelet drug if platelet function testing becomes 
more affordable and accessible in veterinary practice in future.
Use of heparin for management of thrombi has several 
theoretical advantages because venous thromboembolic dis-
ease is classically associated with inappropriate activation of 
the coagulation cascade, rather than abnormal platelet activ-
ity.61 This class of drugs is also used widely in people who 
have similar diseases, including deep vein thrombosis and PTE 
related to recent surgery or cardiac disease.70 Both unfraction-
ated and low-molecular-weight heparin have been administered 
to dogs with IMHA in an attempt to reduce the frequency and 
severity of thromboembolic disease, but the regimens and the 
studies used to evaluate their effects have varied widely.5
Helmond et al71 performed a randomized controlled 
trial to compare the effects of administering unfractionated 
heparin at a conventional and fixed dose from the point of 
diagnosis with those in dogs in whom the dose of heparin was 
adjusted on a daily basis according to the results of repeated 
factor X assays. The latter group of dogs had significantly 
improved survival and required a wider variety of different 
heparin doses to achieve the desired reduction in factor X 
concentration. This study highlights the importance of close 
monitoring of heparin therapy if it is to be instituted; previ-
ous reports in people also indicate that different individuals 
require different doses of unfractionated heparin, limiting 
its use outside of the hospital environment.72 While possibly 
representing a valuable addition to therapy in dogs in whom 
PTE or similar disease is suspected, some forms of heparin 
are expensive, and access to factor X assays is limited to a 
small number of veterinary institutions. Similar assays are 
available at many human hospitals, so monitoring may be fea-
sible if a good working relationship exists with a local center.
Bilirubin encephalopathy
There have been two case reports of dogs suffering neuro-
logical signs that appeared to be related to increased serum 
bilirubin concentrations,73 one in a dog with primary IMHA.74 
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This phenomenon, properly termed bilirubin encephalopathy 
and occasionally kernicterus, has been described most com-
monly in human neonates and rarely in adults with deficient 
activity of the hepatic enzyme uridine diphosphate glucuronyl 
transferase, which is responsible for conjugation of bilirubin.
Bilirubin encephalopathy is suspected in people with 
excessive total serum bilirubin concentrations (usually >500 
mmol/L) who begin to show neurological signs. In the dog with 
IMHA in which it was suspected, magnetic resonance imag-
ing of the brain revealed increased intensity in T2-weighted 
images of the basal ganglia and other central nuclei,74 and post 
mortem examination of both adult dogs diagnosed with the 
disease showed yellow pigmentation of the thalamus.
In clinical practice, the majority of dogs do not develop 
hyperbilirubinemia that is so severe as to result in bilirubin 
encephalopathy, but we believe that this condition should be 
considered in icteric animals that develop neurological signs 
with no other apparent etiology.
Distal renal tubular acidosis
A case series published in 2009 described distal renal tubular 
acidosis in three dogs with IMHA.75 In all three cases, the 
diagnosis was based on the presence of metabolic acidosis 
with normal anion gap and inappropriately high urine anion 
gap and bicarbonate excretion.
The acidemia was treated in all three dogs with infusions 
of sodium bicarbonate, but all were ultimately euthanized. 
Immune-mediated disease is reported to be the most common 
cause of acquired distal renal tubular acidosis in people,76 
particularly in association with systemic lupus erythematosus, 
rheumatoid arthritis, and Sjogren’s syndrome, affecting up 
to one quarter of patients.77–79 It has been suggested that the 
phenomenon develops due to production of autoantibodies that 
interfere with the action of ion transporters in the distal tubule.80
It is not known how frequently distal renal tubular acidosis 
develops in dogs with IMHA or other autoimmune diseases, or 
whether it has any impact on the outcome in affected dogs. In 
people, acidosis is usually treated with potassium citrate rather 
than sodium bicarbonate, as this will treat both acidosis and 
hypokalemia, which are frequently observed concurrently.81
Hemoglobin-related acute kidney injury
Experience gained from treating human injuries during World 
War II suggested that excessive circulating concentrations of 
myoglobin and free hemoglobin could cause acute kidney 
injury, and the same syndrome was produced experimentally 
by injecting hemoglobin into dogs in 1947.82 More recent 
studies suggest that heme proteins cause damage to the 
kidneys in several different ways, including oxidant dam-
age to cellular molecules and changes in blood flow due to 
sequestration of nitric oxide.83
It would appear that azotemic acute kidney injury is not 
common in dogs with IMHA as it has not been reported 
frequently in dogs with this disease, although increased 
serum concentrations of both urea and creatinine have been 
associated with decreased survival in affected dogs.7,10,14,50
Interestingly, a study of dogs at high risk of hemoglo-
bin-induced nephropathy (including dogs with IMHA, 
dogs infected with Babesia canis rossi, and dogs that had been 
injected with large amounts of hemoglobin) reported serum 
creatinine concentrations within normal limits in all groups.84
Glomerular filtration rate was also measured in all indi-
viduals and was reported to be “normal”, but it is not clear 
whether these values were standardized to breed and age 
group reference intervals.
In conclusion, while release of large amounts of free 
hemoglobin into the circulation could increase the risk of 
acute kidney injury, this phenomenon has not been reported 
frequently in the veterinary literature. Furthermore, in animal 
patients with greatly reduced blood oxygen-carrying capacity 
and systemic inflammation, it may be difficult to establish 
whether azotemia has developed due to the effect of heme 
moieties in the kidneys.85
Association between vaccination 
and IMHA
There have been anecdotal reports that recent vaccination 
could be associated with development of IMHA in dogs, 
and a study conducted in the US suggested that dogs with 
IMHA were much more likely to have been vaccinated in the 
month prior to onset of clinical signs than a group of control 
dogs presented for management of other diseases.19 The 
results of this study were not duplicated by another, larger 
investigation, which found no relationship between timing 
of vaccination and onset of clinical signs.22 While there does 
appear to be a consistent relationship between some vaccines 
and development of immune thrombocytopenic purpura in 
people,86 there are only sporadic reports of development of 
acute autoimmune hemolytic anemia after vaccination.87
A topic often raised by owners and veterinarians is whether 
continued vaccination induces relapse of IMHA, but, to our 
knowledge, there have been no published studies reporting the 
frequency of this phenomenon in dogs with IMHA. While there 
is no evidence to suggest that vaccination will cause relapses, 
it is possible for serum antibody titers against canine distemper 
virus, parainfluenza virus, and adenovirus 1 to be measured 
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to guide the decision to vaccinate. Protective antibody titers 
against Leptospira organisms are unlikely to persist beyond 
1 year, so we usually counsel owners and veterinarians that the 
decision to administer this vaccine should be based on a con-
sideration of risks and benefits for the individual animal. For 
example, there may be little indication to vaccinate a dog that 
lives mostly indoors in an area with a low prevalence of Lep-
tospira infections, whereas vaccination may well be indicated 
in working dogs or in dogs that are exposed to waterways.88
Conclusion: future directions and 
comparative aspects
IMHA throws up many challenges for the small animal physi-
cian, and it remains a disease that may respond unpredictably 
or poorly to medication and may still be fatal in a significant 
number of cases. Treatment of canine patients relies almost 
solely on immunosuppression, with splenectomy not uni-
versally used as a reasonable alternative. The situation is 
similar in human medicine wherein steroids remain in use 
as first-line agents with or without cyclophosphamide.89 In 
people, there has been an attempted movement away from 
immunosuppression toward the use of therapeutic mono-
clonal antibodies, though these remain rather nonspecific 
and therefore of mixed efficacy.89 In children particularly, 
treatments with agents such as rituximab, a monoclonal anti-
body against the cluster of differentiation (CD)-20 molecule 
which causes B-cell depletion, are used to avoid high doses 
of steroids or splenectomy, both of which cause significant 
and severe side effects.90 The search for more specific ways 
to treat autoimmune hemolytic anemia in people continues 
and relies on the need to define the origin of the stimulus to 
mount an immune response against red blood cells, so that 
the stimulus can be removed and the immune dysregulation 
corrected. However, this approach may still be some way in 
the future for human and veterinary patients.
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